Hims to acquire UK-based startup Zava as it expands international presence

Hims & Hers (HIMS.N) will acquire UK-based telehealth startup Zava for an undisclosed amount, expanding its reach into Germany, France, and Ireland amid a U.S. regulatory ban on manufacturing mass copies of Wegovy. The acquisition, funded by cash on hand and expected to close in the second half of 2024, follows Hims' recent agreement with Novo Nordisk to provide access to brand-name Wegovy and plans to enter the low testosterone and menopause treatment markets, with shares rising 6.15% in premarket trading following the announcement.

Analysis

Hims & Hers Health, Inc. (HIMS.N) is acquiring UK-based telehealth startup Zava for an undisclosed sum, a strategic move to expand into Germany, France, and Ireland, funded by cash on hand and expected to close in the second half of 2024. This international expansion follows a U.S. regulatory ban effective May 22 on Hims manufacturing mass copies of Novo Nordisk's (NOVOb.CO) weight-loss drug Wegovy, a product that had previously boosted its revenues. To address this regulatory shift and pursue new growth, Hims has also partnered with Novo Nordisk to facilitate patient access to brand-name Wegovy and plans to enter the markets for low testosterone and menopause treatments. The Zava acquisition announcement prompted a 6.15% rise in Hims' shares to $60.26 in premarket trading, partially offsetting a recent approximate 9% decline over the preceding two weeks. Zava currently serves over 1 million customers across the UK and the target European countries, offering medical consultations and prescription medicines, including weight-loss drugs. Hims intends to leverage Zava to introduce personalized skincare, weight loss, and other offerings in these new markets with local language support. Concurrent with these expansion efforts, Hims announced a 4% workforce reduction but affirmed plans to continue hiring for roles related to its long-term growth strategy, with financial details of the Zava deal anticipated with its second-quarter results in August.

Key Decisions for Investors

• Consider Hims' acquisition of Zava as a key strategic initiative to diversify geographically and mitigate U.S. regulatory pressures on its weight-loss segment, presenting a potential catalyst for international revenue growth.
• Scrutinize Hims' second-quarter financial results, expected in August, for the undisclosed financial terms of the Zava acquisition and its implications for the company's cash position and capital allocation strategy.
• Monitor the execution of Hims' European expansion through Zava, the market uptake of its planned new offerings in low testosterone and menopause treatments, and the tangible benefits derived from its partnership with Novo Nordisk, as these will be crucial indicators of future performance.
• Given the recent stock volatility, including a 9% drop followed by a 6.15% premarket rise, investors should assess their risk tolerance while evaluating the long-term growth potential stemming from these strategic shifts against the backdrop of workforce adjustments and an evolving competitive telehealth landscape.